Hymecromone clinical trial is cautiously positive

Robyn Kalda
Jul 7
1 min read

A very small (16 patients) phase 2a clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) looked at whether hymecromone, a drug that might help blood vessels, had any promising effects.

Overall, the results weren't statistically significant, but half the patients treated with hymecromone improved their six-minute walk distance by 66m and had improved quality of life. Researchers concluded that a larger trial is warranted.

Read the Thorax article

Recent Posts

Air pollution may worsen PAH

Air pollution is known to be bad for heart and lung diseases, but this study looked at whether it affected pulmonary arterial hypertension (PAH) in particular. They followed a cohort of patients for a

Kettlebell exercise training was safe and effective for PAH patients

A small study of patients with stable pulmonary arterial hypertension (PAH) were randomly assigned to either no exercise program or an exercise program using kettlebells three days per week for 8 week

Prostacyclin analogues protect against age-related macular degeneration

A study found that people taking infused prostacyclin analogues for pulmonary hypertension had a significantly lower risk of developing age-related macular degeneration, an eye problem that causes vis

Comments